HERON THERAPEUTICS, INC. /DE/ Interest Expense Nonoperating
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Interest Expense Nonoperating of $9.61 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-02-26
- HERON THERAPEUTICS, INC. /DE/ interest expense nonoperating for fiscal 2025 was $9.61M, a 59.23% increase from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ interest expense nonoperating for fiscal 2024 was $6.03M, a 55.95% increase from fiscal 2023.
- HERON THERAPEUTICS, INC. /DE/ interest expense nonoperating for fiscal 2023 was $3.87M, a 56.35% increase from fiscal 2022.
- HERON THERAPEUTICS, INC. /DE/ interest expense nonoperating for fiscal 2022 was $2.47M.
| Period end | Interest Expense Nonoperating 12 month |
|---|---|
| 2025-12-31 | $9.61M 10-K · filed 2026-02-26 |
| 2024-12-31 | $6.03M 10-K · filed 2026-02-26 |
| 2023-12-31 | $3.87M 10-K · filed 2026-02-26 |
| 2022-12-31 | $2.47M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |